echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yaohua Medicine's rare blood disease drug Besremi obtains FDA approval for listing

    Yaohua Medicine's rare blood disease drug Besremi obtains FDA approval for listing

    • Last Update: 2021-12-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    CompilationFan Dongdong

    Eight months after the failure of the last listing application, Pharma Essentia successfully alleviated the concerns of the US FDA.

    In March of this year, the U.

    The US FDA approval is based on the safety of PEGINVERA and PROUD/CONTINUATION-PV studies and the efficacy data from the PEGINVERA clinical research program

    The injected drug is approved for the treatment of adult patients with polycythemia vera, a rare blood disease that causes blood to thicken and affects approximately 6,200 people in the United States each year

    In addition, Pharma Essentia said that the US FDA’s previous refusal was due to the delay of pre-approval inspections of its manufacturing plant in Taiwan Province of China due to travel restrictions on the COVID-19 pandemic

    The therapy can bind to interferon receptors and trigger the process of reducing red blood cell production in the bone marrow

    In terms of competitors, Incyte's Jakafi was approved as a second-line treatment for polycythemia vera, while Besremi approved the first-line treatment this time

    Reference source: Second time's a charm for PharmaEssentia as FDA approves Besremi to treat rare blood cancer

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.